<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Posts in: In the News

Biodesix Named Company of the Year by Colorado BioScience Association

Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association. The company was honored at the 16th Annual CBSA Awards Dinner.

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.

Biodesix Appoints Scott Hutton as Chief Executive Officer

Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.

Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.

Biodesix Completes Acquisition of Oncimmune Assets in the United States

Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.

Biodesix Names Dr. James Jett Chief Medical Officer

Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.

Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD).